Verrica Pharmaceuticals Reports Record Growth in YCANTH® Dispensed Units for Molluscum Contagiosum Treatment
Verrica Pharmaceuticals achieved a milestone with over 10,000 YCANTH® dispensed applicator units in Q1 2025, representing a 16.7% sequential increase from the previous quarter.
Basal Cell Carcinoma Market Set to Reach $9.7 Billion by 2035, Driven by Early Detection and Novel Therapies
The global basal cell carcinoma market is projected to grow from $5.48 billion in 2024 to $9.7 billion by 2035, exhibiting a CAGR of 5.34% according to IMARC Group research.
Torii Pharmaceutical Submits NDA in Japan for Verrica's Molluscum Contagiosum Treatment, TO-208
Torii Pharmaceutical has submitted a New Drug Application (NDA) in Japan for TO-208, a cantharidin-based treatment for molluscum contagiosum.
Lytix Biopharma's LTX-315 Demonstrates Strong Efficacy in Skin Cancer Trials, Eyes Phase III
Lytix Biopharma's LTX-315 showed an impressive 97% objective response rate in a Phase II study for basal cell carcinoma, potentially as a first-line treatment.
LTX-315 Shows Promise in Phase II Trial for Basal Cell Carcinoma
LTX-315 (VP-315) demonstrated significant anti-cancer effects in a Phase II clinical study for basal cell carcinoma (BCC).
LTX-315 Shows Promise in Basal Cell Carcinoma Treatment
Lytix Biopharma's LTX-315 (VP-315), in partnership with Verrica Pharmaceuticals, demonstrates positive Phase II results for basal cell carcinoma (BCC) treatment.
VP-315 Demonstrates Tumor Reduction in Basal Cell Carcinoma Phase 2 Trial
Preliminary phase 2 data shows VP-315 led to tumor size reduction in 86% of basal cell carcinoma patients, indicating a potential new treatment option.